8
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Photoaffinity Ligands for the [3H]tbob Binding Site of the GabaA Receptor

, , &
Pages 391-405 | Published online: 26 Sep 2008
 

Abstract

Two types of 1–substituted-4-t-butyl-2,6,7–trioxabicyclo(2.2.2]octanes are examined as candidate photoaffinity ligands to irreversibly inhibit the [3H]TBOB binding site of the GABAA receptor complex present in bovine brain membranes. The 1–substituted-(4–bromo-6–diazocyclohexa-1,4–dien-3–onyl) derivative (lC50 1.1,μM) dissociates completely in the dark, but on irradiation produces over 40% photoirreversible inhibition of [3H]TBOB binding. This photoinactivation can be partially (64%) protected using a potent and completely dissociating TBOB analog. The 1–substituted-(4–azidopnenyl) derivative (lC50 149 nM) also dissociates completely in the dark and at 2.2 μM gives 20% photoirreversible inhibition which is completely protectable. The corresponding 1–(4–azido-3,5–dichlorophenyl) analog and its 4–(1–methylpropyl) isomer are 16– and 8–fold more potent inhibitors, respectively, than the azidophenyl derivative but these dichloro probes are not examined further because they do not dissociate in the dark by an apparently non-covalent mechanism. Thus, the bromodiazocyclohexadienonyl and azidophenyl compounds photoirreversibly and therefore covalently modify the [3H]TBOB binding site of the GABAA receptor complex.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.